16 RESULTS
Go to another page:
COMMENT Institutes for Health Research, with the terse comment, “This is a ridiculous hypothesis.” It did more than
COMMENT In our comments to Alzforum on 17 February 2012, we reported our failure to confirm the data of
COMMENT The report by Cramer et al. is potentially exciting because it offers a plausible explanation as to why ApoE4 should be a risk factor for AD, and more importantly suggests that bexarotene, an off-the-shelf retinoid X receptor agonist, may prove to be an e
COMMENT The paper by Lemere and colleagues provides further evidence for the role that the complement system plays in inflammation generally, and in Aβ phagocytosis particularly. The group developed a double transgenic APP and complement C3-deficient mouse model
COMMENT The ADAPT trial was a bold attempt to determine if cyclooxygenase (COX) inhibitors could prevent cognitive decline, but it was flawed from the start by the unfortunate choice of celecoxib and naproxen as the agents to test. Celecoxib should never have bee
COMMENT Dr. Ed Tobinick has developed a revolutionary approach to deal with the neuroinflammatory damage which occurs in AD. He has administered Enbrel®, a soluble TNF blocker which is too large to cross the blood-brain barrier, perispinally to AD patients. The c
COMMENT Butovsky and colleagues have reported that “Glatiramer acetate fights against Alzheimer’s disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.” The authors have not shown that glatiramer fights against AD, per se. They do
COMMENT Tabaton, and Nikolaos Robakis have each made thoughtful and pertinent comments about our paper. Our
COMMENT Nimmerjahn et al. have used the two-photon imaging technique to demonstrate the dynamic action of microglial cells in vivo. They were provided with a green fluorescent microglia cell line by S. Jung and D.R. Littman. In their elegantly illustrated paper,
COMMENT Comment by Pat McGeer and Andis Klegeris Ramirez et al., in their paper on prevention of Alzheimer
COMMENT The key point of the Furlan et al. paper is that they used pertussis toxin as a necessary adjuvant to produce the autoimmune encephalitis; that is not the protocol of others who carried out Aβ vaccination experiments in transgenic mice. The results are ne
COMMENT Tan et al. have created doubly transgenic mice which overexpress APP(sw) and are deficient in CD40 ligand (CD40L). They find that these doubly transgenic mice have a greatly reduced burden of amyloid deposits compared to the singly transgenic APP mice. Tr
COMMENT The nimesulide trial represents another failure in applying the epidemiological evidence of NSAIDs protecting against AD toward successful treatment. There are some simple explanations for this failure. First of all, a mismatch exists between the NSAIDs u
COMMENT trials of traditional NSAIDs. Nevertheless, there are many comments in the literature expressing doubt
COMMENT in his comments that microglial activation is a beneficial phenomenon up to the level where host
Go to another page:
